JP2010509326A5 - - Google Patents

Download PDF

Info

Publication number
JP2010509326A5
JP2010509326A5 JP2009536219A JP2009536219A JP2010509326A5 JP 2010509326 A5 JP2010509326 A5 JP 2010509326A5 JP 2009536219 A JP2009536219 A JP 2009536219A JP 2009536219 A JP2009536219 A JP 2009536219A JP 2010509326 A5 JP2010509326 A5 JP 2010509326A5
Authority
JP
Japan
Prior art keywords
composition
food
balsalazide
acid compound
aminosalicylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009536219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509326A (ja
JP6067203B2 (ja
Filing date
Publication date
Priority claimed from US11/592,854 external-priority patent/US8921344B2/en
Application filed filed Critical
Publication of JP2010509326A publication Critical patent/JP2010509326A/ja
Publication of JP2010509326A5 publication Critical patent/JP2010509326A5/ja
Application granted granted Critical
Publication of JP6067203B2 publication Critical patent/JP6067203B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009536219A 2006-11-03 2007-03-23 ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用 Expired - Fee Related JP6067203B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/592,854 2006-11-03
US11/592,854 US8921344B2 (en) 2006-11-03 2006-11-03 Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
PCT/US2007/007438 WO2008063211A2 (en) 2006-11-03 2007-03-23 Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012248573A Division JP2013032395A (ja) 2006-11-03 2012-11-12 ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用

Publications (3)

Publication Number Publication Date
JP2010509326A JP2010509326A (ja) 2010-03-25
JP2010509326A5 true JP2010509326A5 (enExample) 2011-03-03
JP6067203B2 JP6067203B2 (ja) 2017-01-25

Family

ID=38263983

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009536219A Expired - Fee Related JP6067203B2 (ja) 2006-11-03 2007-03-23 ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用
JP2012248573A Pending JP2013032395A (ja) 2006-11-03 2012-11-12 ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012248573A Pending JP2013032395A (ja) 2006-11-03 2012-11-12 ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用

Country Status (12)

Country Link
US (1) US8921344B2 (enExample)
EP (1) EP2096912B1 (enExample)
JP (2) JP6067203B2 (enExample)
KR (2) KR20090118906A (enExample)
CN (1) CN101610670A (enExample)
AU (1) AU2007322362B2 (enExample)
BR (1) BRPI0717859A2 (enExample)
CA (2) CA2668441C (enExample)
DK (1) DK2096912T3 (enExample)
IL (1) IL198513B (enExample)
MX (1) MX2009004826A (enExample)
WO (1) WO2008063211A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
EP2361620B1 (en) 2004-02-06 2016-04-06 PHARMATEL (R&D) PTY LIMITED as Trustee for the PHARMATEL (R & D) TRUST Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US8436051B2 (en) * 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
ITMI20071965A1 (it) * 2007-10-11 2009-04-12 Domenico Russo Composizione farmaceutica comprendente sucralfato e mesalazina
CA2739465C (en) * 2008-10-03 2017-01-31 Dr. Falk Pharma Gmbh Compositions and methods for the treatment of bowel diseases with granulated mesalamine
US20120111756A1 (en) * 2008-12-17 2012-05-10 Altheus Therapeutics, Inc. Enema formulations
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
AU2011245455A1 (en) * 2010-04-26 2012-11-15 Salix Pharmaceuticals, Ltd. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
PL3884947T3 (pl) * 2010-12-03 2024-05-06 Nalpropion Pharmaceuticals Llc Wzrost biodostępności leku w terapii naltreksonem
CN103333084B (zh) * 2013-06-09 2015-01-07 陕西新药技术开发中心 3,3’-偶氮双[6-(丁酰氧基)苯甲酸]及其制备方法和应用
CN103483220B (zh) * 2013-06-09 2015-06-17 陕西新药技术开发中心 一种化合物及其制备方法和抗溃疡性结肠炎用途
CN104706582A (zh) * 2013-12-12 2015-06-17 四川健能制药有限公司 含有美沙拉秦的药物组合物
US10100005B1 (en) * 2017-11-17 2018-10-16 Eclipse Therapeutics, LLC Mesalazine derivatives
JP2020090456A (ja) * 2018-12-05 2020-06-11 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4298595A (en) * 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
WO1981002671A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
EP0039306B1 (de) * 1980-03-28 1984-01-11 Ciba-Geigy Ag Neue Azofarbstoffe, Verfahren zu deren Herstellung und deren Verwendung
US4412922A (en) * 1980-07-02 1983-11-01 Abcor, Inc. Positive-charged ultrafiltration membrane for the separation of cathodic/electrodeposition-paint compositions
US4412992A (en) 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4562024A (en) * 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
SE8405924L (sv) * 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
US4781925A (en) * 1986-03-06 1988-11-01 American Home Products Corporation Calcium supplement compressed tablets
US5374430A (en) * 1986-09-18 1994-12-20 London School Of Pharmacy Pharmaceutical formulation
EP0439453B1 (en) * 1987-10-12 1994-01-19 Exomed Australia Pty. Ltd. (ACN 051 976 446) Improved method for treatment of gastrointestinal disorders
US5064637A (en) * 1989-05-30 1991-11-12 Board Of Regents, The University Of Texas System Substituted sulfonamide derivatives which inhibit allergic reactions
US5095073A (en) * 1990-03-02 1992-03-10 Exxon Research And Engineering Company Water soluble rigid rod sulfonated aromatic polyamide
SE9003296L (sv) 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
ES2111659T3 (es) * 1992-03-11 1998-03-16 Asta Medica Ag Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion.
US5498608A (en) 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
JPH08169847A (ja) 1994-12-16 1996-07-02 Morishita Roussel Kk 固形製剤
US5905073A (en) * 1995-01-06 1999-05-18 Salix Pharmaceuticals, Inc. Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation
DE69839261T2 (de) * 1997-04-01 2009-03-26 Borody, Thomas Julius, Five Dock Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
US20030078205A1 (en) * 2001-07-31 2003-04-24 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
US6144381A (en) * 1997-05-14 2000-11-07 International Business Machines Corporation Systems, methods and computer program products for compass navigation of avatars in three dimensional worlds
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
ATE321066T1 (de) 1998-05-06 2006-04-15 Genentech Inc Anti-her2 antikörperzusammensetzung
US5927500A (en) * 1998-06-09 1999-07-27 Milliken & Company Pharmaceutical containment package
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6517871B1 (en) * 1998-07-20 2003-02-11 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
KR20000011247A (ko) 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US20030138399A1 (en) * 1999-05-14 2003-07-24 Anton Peter A. Anti-inflammatory therapy for inflammatory mediated infection
EP1313699B1 (en) * 2000-08-29 2010-03-10 Biocon Limited 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
DE60115465T2 (de) * 2000-08-29 2006-08-03 Nobex Corp. Immunoregulierende verbindungen, deren derivate und ihre verwendung
US6562871B1 (en) * 2000-11-06 2003-05-13 Boehringer Ingelheim Pharmaceuticals, Inc. Dry granulation of pharmaceutical formulation comprising mexiletine
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
AU2003226752A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Venlafaxine base
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
JPWO2004082715A1 (ja) 2003-03-20 2006-06-22 エーザイ株式会社 炎症性腸疾患治療剤としての併用医薬
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
WO2005030173A1 (en) 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Colon-specific drug delivery using interpolymer complexations
EP2361620B1 (en) 2004-02-06 2016-04-06 PHARMATEL (R&D) PTY LIMITED as Trustee for the PHARMATEL (R & D) TRUST Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome
EP2529729A1 (en) * 2005-08-24 2012-12-05 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US20100048519A1 (en) * 2006-09-13 2010-02-25 Chyon-Hwa Yeh Methods of treatment for ulcerative colitis using aminosalicylate

Similar Documents

Publication Publication Date Title
JP2010509326A5 (enExample)
JP2019048843A5 (enExample)
JP2009514874A5 (enExample)
JP2014528474A5 (enExample)
AU2007267135A1 (en) Long term 24 hour intestinal administration of levodopa/carbidopa
JP2009529502A5 (enExample)
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
JP2012520866A5 (enExample)
JP2008520736A5 (enExample)
WO2008122190A1 (en) The composition comprising l-carnitine or derivatives thereof and its use
AU2010200722A1 (en) Methods of treating non-painful bladder disorders using Alpha2Delta subunit calcium channel modulators
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
WO2008030830A3 (en) Sustained-release composition and method of use thereof
Dutta et al. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States
IL272834B1 (en) Compositions of amantadine, their preparation, and methods of use
TW200534852A (en) 4-methylpyrazole formulations for inhibiting ethanol intolerance
CN103919774A (zh) 去亚甲基小檗碱在制备降血脂药物中的应用
AU2019237857B2 (en) Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
CN114007608A (zh) 在儿科患者中治疗无义突变介导的杜氏肌营养不良症的方法
JP2009522294A5 (enExample)
RU2016144695A (ru) Комплекс танната ситаглиптина
AU2004268381B2 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
JP5376785B2 (ja) 医薬組成物
JP5376786B2 (ja) 神経細胞賦活組成物
WO2006064744A1 (ja) 糖尿病の治療のための医薬組成物